Introduction {#section5-1947603511414178}
============

Osteoarthritis (OA) is the most common form of arthritis and has a prevalence of about 10% in people over 55 years of age.^[@bibr1-1947603511414178]^ The hallmark of OA involves joint pain and reduced mobility that is caused by erosion of the cartilage extracellular matrix and alterations in the underlying bone. Although the extracellular matrix is the functional element in articular cartilage and its degradation is central in the pathogenic process in OA, there is now abundant evidence that chondrocytes play a critical role in cartilage degeneration. For instance, OA chondrocytes secrete a variety of enzymes and cytokines, resulting in cleavage of type II collagen.^[@bibr2-1947603511414178]^ OA chondrocytes, compared to normal chondrocytes, are further in another differentiation state, detected by their increased expression of collagen types I, III, and X.^[@bibr3-1947603511414178]^ Therefore, increasing the knowledge about the cellular alterations in OA chondrocytes is essential for generating new therapies for patients suffering from OA.

WNT signaling has been shown to regulate crucial aspects of cell fate determination, cell migration, cell polarity, and organogenesis during embryonic development and is therefore of importance to study in OA cartilage. WNT regulates at least 3 distinct signaling pathways; the canonical β-catenin pathway regulates cell fate determination, while the 2 noncanonical pathways (planar cell polarity and Ca^2+^/WNT pathway) control cell movement and tissue polarity.^[@bibr4-1947603511414178]^ Signaling through these 3 different WNT pathways is dependent upon WNTs, which are secreted glycoproteins. Today, 19 different WNT proteins have been discovered that bind to several different types of receptors, but the most widely recognized WNT receptors are the frizzled proteins (FZD). The FZD receptors are 7-transmembrane--spanning proteins and constitute a family of at least 10 different G protein--coupled receptors. Downstream of this ligand-receptor interaction, the 3 WNT signaling pathways diverge. With regard to the canonical WNT signaling, FZD coreceptors such as LRP5/6 are also required for translocation of the signal. Several secreted WNT antagonists, such as DKK, SFRP, and WIF, exert a key level of regulation of canonical WNT signaling. The activation of FZD and LRP5/6 triggers phosphorylation of DVL, which disrupts the β-catenin degradation complex, consisting of AXIN, APC, and GSK-3β. This complex normally degrades β-catenin through phosphorylation; however, when WNTs bind FZD, β-catenin levels are stabilized and translocated into the nucleus, resulting in transcription of downstream canonical WNT markers. The noncanonical pathways are less studied. They function independently of β-catenin.^[@bibr5-1947603511414178]^ Still, the FZD receptor is of importance for signaling but also coreceptors such as ROR2 and RYK, but not LRP5/6.^[@bibr6-1947603511414178]^

A few studies have been performed investigating the expression of WNT markers during cartilage development, demonstrating an altered expression depending on the differentiation state of the chondrocytes.^[@bibr7-1947603511414178]-[@bibr12-1947603511414178]^ Compared to the knowledge obtained concerning the importance of WNT signaling during cartilage development, relatively little is known regarding the role of WNT signaling in the maintenance and destruction of cartilage. Interleukin-1 is known to increase cartilage matrix degradation, and chondrocytes stimulated with this cytokine increase their expression of WNT5A while decreasing their expression of WNT11.^[@bibr13-1947603511414178]^ Further evidence for the importance of WNT signaling in OA cartilage is the increased levels of β-catenin in chondrocytes within areas of degenerative cartilage.^[@bibr14-1947603511414178],[@bibr15-1947603511414178]^ Moreover, microarray analysis of the underlying bone suggests that the WNT network is altered in OA bone and may play a role(s) in OA pathogenesis.^[@bibr16-1947603511414178]^

Differential regulation of WNT markers during cartilage development, recent findings concerning the importance of WNT signaling for OA, as well as the shortage of knowledge regarding the expression pattern of WNT markers in OA cartilage prompted us to comprehensively investigate the expression of WNT markers in human OA cartilage. We have earlier reported a broad gene expression comparison of human OA and normal donor cartilage and here use this unique database to focus on investigating the expression of WNT markers.^[@bibr17-1947603511414178]^ This knowledge will expand our current understanding of OA pathogenesis and provide relevant insight into the phenotypical alterations and mechanisms involved in OA pathogenesis.

Materials and Methods {#section6-1947603511414178}
=====================

Collection of Biopsies {#section7-1947603511414178}
----------------------

Cartilage biopsies from 5 OA patients (74 ± 8 years old) undergoing total knee replacement and 8 control donors (57 ± 16 years old) with macroscopically healthy cartilage and with a Mankin score ≤1 were collected from organ donors (24-48 hours, *post mortem*) (normal donors \[NDs\]) as described earlier.^[@bibr17-1947603511414178]^ These biopsies were further used for immunohistological detection of WNT markers (see below). The rest of the biopsies were used for RNA isolation and subsequent microarray analysis. ND and OA cartilage was also collected for subsequent cell cultures. The donation of cartilage was approved by the ethical committees at the Medical Faculties at Gothenburg University and Charité-Universitätsmedizin Berlin.

RNA Isolation {#section8-1947603511414178}
-------------

Cartilage biopsies were processed for RNA isolation.^[@bibr17-1947603511414178]^ Briefly, after mechanical disruption, isolation of total RNA was performed using the Qiagen RNeasy Mini Kit (Hilden, Germany), and the integrity and purity were analyzed using the Agilent Bioanalyzer and NanoDrop spectrophotometer (Santa Clara, CA). All samples were of similar RNA quality and integrity with limited signs of degradation typical for primary tissues.

Microarray Analysis {#section9-1947603511414178}
-------------------

Gene expression was performed using Affymetrix oligonucleotide microarray HG-U133plus2.0 (Santa Clara, CA) according to the manufacturer's recommendations, as previously described.^[@bibr17-1947603511414178]^ Genes were regarded as differentially expressed when fulfilling specific change call criteria. In this study, the limit was set to at least ≥75% possible significant change calls. Functional classification of genes involved in WNT signaling was conducted with annotations from the Gene Ontology Annotation Database.^[@bibr18-1947603511414178]^ Downstream *t* test statistics applying the Welch test on log~2~-transformed signal values were performed to obtain a significance level. Expression differences were given as fold changes (FCs); only significantly altered genes that displayed a mean fold change of FC ≥2 or ≤−2 were selected for further analysis. Hierarchical cluster analysis was performed as described previously.^[@bibr17-1947603511414178]^

Pathway Analysis {#section10-1947603511414178}
----------------

In order to identify significant differently expressed pathways in OA and ND cartilage, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database^[@bibr19-1947603511414178]^ was searched using DAVID software tools.^[@bibr20-1947603511414178],[@bibr21-1947603511414178]^ All genes on the array fulfilling the specific criteria used in this study (see above) were included in the gene list.

Quantitative Real-Time PCR Analysis {#section11-1947603511414178}
-----------------------------------

The following assay-on-demand mixes were used from Applied Biosystems (Foster City, CA) (order number in parentheses): *DKK1* (Hs00183740_m1), *FOSL1* (Hs00759776_s1), *FZD1* (Hs00268943_s1), *SFRP4* (Hs00180066_m1), *WNT5A* (Hs00180103_m1), which were all FAM dye labeled. 18s rRNA (4310893E) labeled with VIC/TAMRA was used as endogenous control. PCR was performed with the Applied Biosystems 7900HT real-time PCR System. cDNA from 6 NDs and 5 OA donors, corresponding to 1 ng total RNA isolated from the cartilage biopsies, and 2.5 ng total RNA from the monolayer cultured cells isolated from 3 NDs and 3 OA donors were analyzed in duplicates. Raw data were analyzed by using SDS v2.2.2 software (Applied Biosystems), and the 2^--ΔΔCt^ value was used to obtain the gene expression for each particular gene. Statistical analysis was performed using the Mann-Whitney *U* test (cartilage biopsies) and Wilcoxon paired signed-rank test (monolayer cultured cells). Values of *P* \< 0.05 were considered to indicate statistically significant differences.

Immunohistochemistry {#section12-1947603511414178}
--------------------

Immunohistochemistry was performed on 5 OA and 4 ND sections in duplicates from articular cartilage for AXIN2, DKK1, DKK3, and WNT5A. Slides for labeling with AXIN2 and DKK3 were digested with trypsin 0.05% EDTA, while labeling with DKK1 and WNT5A was preceded by protease treatment (1 mg/mL; Sigma-Aldrich, St. Louis, MO). Additional enzyme treatment with hyaluronidase (8000 U/mL; Sigma-Aldrich) was performed for DKK1. The sections were blocked with 3% BSA. Primary antibodies (rabbit polyclonal anti-AXIN2, rabbit polyclonal anti-DKK, rabbit polyclonal anti-DKK3, and goat polyclonal anti-WNT5A) were purchased from Abcam (Cambridge, MA), Sigma-Aldrich, and R&D Systems (Minneapolis, MN), respectively. An isotype control for each primary antibody was used as control: normal rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA) for AXIN2 and DKK1 as well as rabbit polyclonal IgG (Abcam) for DKK3 and normal goat IgG for WNT5A. The primary antibodies and the isotype controls were visualized using HRP-conjugated secondary antibodies (sheep anti-rabbit HRP \[Millipore, Billerica, MA\] and donkey anti-goat HRP). The secondary antibodies were visualized using the TSA-Direct Cy3 kit (Perkin Elmer, Boston, MA) according to the manufacturer's instructions. The nuclei were stained with 4',6-diamidino-2-phenylindol (DAPI) (Sigma-Aldrich). Digital pictures were taken with the NIS-Elements D Ver.3.00 (Nikon, Tokyo, Japan).

Analysis of Protein Interaction Networks {#section13-1947603511414178}
----------------------------------------

To investigate possible interactions among proteins coded by genes that were differentially regulated (defined by having a mean FC ≥3 or ≤−3) between NDs and OA donors, the protein interaction analysis was performed as described previously.^[@bibr17-1947603511414178]^

Chondrocyte Isolation {#section14-1947603511414178}
---------------------

Chondrocytes were isolated from 3 ND and 3 OA cartilage biopsies as described previously.^[@bibr22-1947603511414178]^ The isolated cells were expanded in medium consisting of DMEM/F12 (Invitrogen, Paisley, UK) supplemented with L-ascorbic acid (0.025 mg/mL; Apotekets production unit, Umeå, Sweden), gentamicin sulfate (50 mg/L; Gibco, Paisley, UK), amphotericin B (250 µg/mL), and L-glutamine (2 mM; Gibco) and 10% human serum.

Cytokine Stimulation of Chondrocytes {#section15-1947603511414178}
------------------------------------

Chondrocytes, isolated from 3 NDs and 3 OA donors, in passage 1 were stimulated with 10 ng/mL of human recombinant interleukin-1β (Sigma-Aldrich) for 24 hours or left unstimulated. Gene expression of WNT markers was then studied in duplicates using real-time PCR, as described above.

Results {#section16-1947603511414178}
=======

Characterization of OA and ND Cartilage {#section17-1947603511414178}
---------------------------------------

For an extensive verification of the NDs and OA phenotypes, see Karlsson *et al*.^[@bibr17-1947603511414178]^ Briefly, all OA donors displayed an Ahlbäck score of 2 to 3. Mankin scoring of the cartilage biopsies demonstrated significant differences between ND and OA articular cartilage biopsies (0.8 ± 0.15 and 6.4 ± 1.3, respectively).

Pathway Analysis in OA versus ND Cartilage {#section18-1947603511414178}
------------------------------------------

In order to explore pathways that could be differentially expressed in OA versus ND cartilage, the KEGG pathway database was searched using the genes regarded as significantly differentially expressed as input. The analysis demonstrated 26 pathways that show a significantly different expression in OA compared to ND cartilage, whereas 10 of the most significantly expressed pathways are listed in [**Table 1**](#table1-1947603511414178){ref-type="table"}. The presence of the WNT signaling pathway demonstrates that the WNT network is dysregulated in OA compared to ND cartilage.

###### 

Differentially Expressed Pathways in Osteoarthritic (OA) versus Normal Donor (ND) Cartilage

  KEGG ID    Pathway Term                                Count   *P* Value
  ---------- ------------------------------------------- ------- -----------
  hsa04512   Extracellular matrix receptor interaction   29      9.28E-10
  hsa04510   Focal adhesion                              43      4.12E-7
  hsa05130   Pathogenic *Escherichia coli* infection     18      1.10E-5
  hsa05200   Pathways in cancer                          52      1.81E-4
  hsa05222   Small cell lung cancer                      18      1.81E-3
  hsa04810   Regulation of actin cytoskeleton            34      3.11E-3
  hsa04310   Wnt signaling pathway                       26      3.53E-3
  hsa04115   p53 signaling pathway                       15      3.81E-3
  hsa04722   Neurotrophin signaling pathway              22      5.53E-3
  hsa05221   Acute myeloid leukemia                      13      6.87E-3

Note: Pathway analysis using the KEGG pathway database with significantly different expression in OA compared to ND cartilage. Only 10 (of 26) of the most significant differentially expressed pathways are shown. Count indicates the total number of genes from the input list that belong to the corresponding term; only significantly expressed genes that displayed a mean fold change (FC) of ≥2 or ≤−2 were included in the gene list.

WNT Markers Are Differentially Regulated in OA Cartilage {#section19-1947603511414178}
--------------------------------------------------------

Due to the results obtained from the KEGG pathway analysis, a cluster analysis was performed of all genes denoted to be involved in WNT signaling. The analysis revealed 2 distinct clusters, one with OA cartilage and one with ND cartilage ([**Fig. 1**](#fig1-1947603511414178){ref-type="fig"}). These separate clusters thus demonstrate that the expression of WNT markers is significantly altered in OA cartilage.

![Hierarchical cluster analysis of genes involved in WNT signaling. Hierarchical cluster analysis of genes known to be associated with WNT signaling demonstrated that cartilage from the 5 donors with normal cartilage (ND1-ND5) formed one cluster and cartilage from osteoarthritic donors (OA1-OA5) formed another cluster, showing significantly altered WNT signaling in OA cartilage.](10.1177_1947603511414178-fig1){#fig1-1947603511414178}

Increased Expression of Genes Encoding Inhibitors of the WNT Signaling Pathway in OA Cartilage {#section20-1947603511414178}
----------------------------------------------------------------------------------------------

Our results from the microarray analysis demonstrate that the expression of 32 genes associated with WNT signaling was significantly regulated between OA and ND cartilage ([**Table 2**](#table2-1947603511414178){ref-type="table"}). Of interest to note is that several inhibitors of the canonical and planar cell polarity WNT signaling pathways displayed an increased expression in OA cartilage. The expression of important extracellular inhibitors of the canonical pathway, including *DKK1*, *DKK3*, *WIF1*, *SFRP1*, and *SFRP4*, was significantly upregulated in the OA biopsies, with a 3.9, 3.9, 3.1, 8.1, and 14.2 FC, respectively. Several homologs of the FZD receptor (*FZD1*, *FZD7*, *FZD8*, and *FZD10*) also displayed increased expression in OA cartilage. Expression of intracellular and intranuclear inhibitors was also upregulated in the OA biopsies, including genes involved in β-catenin phosphorylation and its destruction, such as *AXIN2*, *SOX17*, and *TAX1BP3*. Furthermore, the transcriptional repressor *TLE4* displayed a 2.3-fold higher expression in OA than in ND biopsies, whereas *TCF7L2* was downregulated 2.5-fold. On the other hand, genes transcribed when the canonical WNT signaling is activated, such as *FOSL1* and *PPARD*, exhibited an increased expression in OA cartilage. Our results further demonstrate that the planar cell polarity pathway was inhibited. Expression of several markers for this pathway, such as *PRICKLE2*, *DVL2*, and *DAAM2*, was significantly downregulated 2.1-, 3.4-, and 3.8-fold, respectively, in OA cartilage. However, genes denoted to the Ca^2+^/WNT pathway displayed an increased expression. Among them, *WNT5A*, *CAMKII*, *NFAT5*, and *NFATC2* expression was significantly upregulated 16.0-, 3.2-, 4.3-, and 8.2-fold, respectively, in OA cartilage. These extended microarray results are summarized in [**Figure 2**](#fig2-1947603511414178){ref-type="fig"}.

###### 

WNT Related Genes Revealed in the Microarray Analysis

  Gene Name                                                    Gene Symbol   Probe ID       Public ID      FC OA versus ND   *P* Value
  ------------------------------------------------------------ ------------- -------------- -------------- ----------------- -------------
  Extracellular                                                                                                              
  Wingless-type MMTV integration site family, member 5         WNT5A         205990_s\_at   NM_003392      16.0              6.92735E-15
  Secreted frizzled-related protein 4                          SFRP4         204051_s\_at   AW089415       14.2              1.38979E-25
  Secreted frizzled-related protein 1                          SFRP1         202037_s\_at   NM_003012      8.1               1.45767E-12
  Dickkopf homolog 1                                           DKK1          204602_at      NM_012242      3.9               4.24038E-6
  Dickkopf homolog 3                                           DKK3          202196_s\_at   NM_013253      3.9               1.18684E-5
  WNT inhibitory factor 1                                      WIF1          204712_at      NM_007191      3.1               2.26111E-5
  Membrane bound                                                                                                             
  Frizzled homolog 8                                           FZD8          227405_s\_at   AW340311       13.4              8.92757E-26
  Frizzled homolog 10                                          FZD10         219764_at      NM_007197      6.7               6.72813E-30
  Vang-like 1                                                  VANGL1        219330_at      NM_024062      4.8               5.55668E-17
  Sulfatase 1                                                  SULF1         212353_at      AI479175       4.3               4.29776E-11
  Frizzled homolog 7                                           FZD7          203706_s\_at   NM_003507      4.0               3.13684E-24
  Frizzled homolog 1                                           FZD1          204452_s\_at   AF072872       3.8               3.07887E-13
  Intracellular                                                                                                              
  Peroxisome proliferator--activated receptor δ                PPARD         242218_at      AI201116       12.8              9.55763E-8
  FOS-like antigen 1                                           FOSL1         204420_at      BG251266       9.1               3.88083E-11
  Transcript factor NFAT1 isoform C                            NFATC2        226991_at      NM_001136021   8.2               4.32651E-13
  Nuclear factor of activated T-cells 5, tonicity responsive   NFAT5         215092_s\_at   NM_001113178   4.3               3.4648E-4
  Casein kinase 1 ϵ                                            CSNK1E        226858_at      ---            3.5               2.73695E-8
  Calmodulin-dependent protein kinase II α                     CAMK2A        213108_at      NM_015981      3.2               1.36801E-6
  SRY-box 17                                                   SOX17         219993_at      NM_022454      2.7               2.70202E-7
  Transducin-like enhancer of split 4 E (sp1) homolog          TLE4          204872_at      NM_007005      2.3               2.82611E-8
  Axin 2                                                       AXIN2         222696_at      BF684446       2.3               7.11705E-14
  Tax1-binding protein 3                                       TAX1BP3       209154_at      AF234997       2.1               5.9216E-12
  DIX domain containing 1                                      DIXDC1        214724_at      AF070621       2.1               5.99097E-16
  F-box and WD repeat domain containing 4                      FBXW4         221519_at      AF281859       −2.0              7.8246E-19
  Prickle homolog 2                                            PRICKLE2      225968_at      BG285881       −2.1              4.51586E-11
  Protein phosphatase 2 regulatory subunit B, α isoform        PPP2R2A       202313_at      NM_002717      −2.1              1.24529E-10
  HMG-box transcription factor 1                               HBP1          209102_s\_at   AF019214       −2.2              3.19294E-15
  C-terminal--binding protein 2                                CTBP2         201218_at      N23018         −2.4              5.83668E-12
  Casein kinase 2, α prime polypeptide                         CSNK2A2       203575_at      NM_001896      −2.4              4.59298E-13
  Transcription factor 7--like 2                               TCF7L2        216511_s\_at   ---            −2.5              1.03935E-12
  Disheveled-associated activator of morphogenesis 2           DAAM2         212793_at      BF513244       −3.4              2.16355E-17
  Disheveled, dsh homolog 2                                    DVL2          218756_at      NM_004422      −3.8              2.2239E-9

Note: Genes whose expression is differentially regulated between osteoarthritic (OA) and normal donor (ND) cartilage and that are associated with WNT signaling. Genes are divided into genes encoding extracellular, transmembrane, and intracellular proteins. Expression differences are given as fold change (FC); only genes with an FC ≥2 or ≤−2 are shown. Genes with a positive FC are upregulated in OA cartilage when compared with ND cartilage.

![Schematic summary of the results obtained from the microarray analysis. Genes in red boxes negatively regulate the WNT signaling pathway, whereas the green boxes indicate a positive regulation of the network. A "±" sign after the gene name refers to a positive (higher gene expression in OA cartilage) or negative (lower gene expression in OA cartilage) fold change (FC) in the microarray analysis.](10.1177_1947603511414178-fig2){#fig2-1947603511414178}

Increased Gene Expression of FOSL1, FZD8, NFATC2, SFRP1, SFRP4, and WNT5A in OA Cartilage {#section21-1947603511414178}
-----------------------------------------------------------------------------------------

To verify the microarray data, a quantitative real-time PCR analysis was performed for 7 of the most highly differentially expressed WNT-related genes comparing OA and ND cartilage according to the microarray analysis. The real-time PCR verification demonstrated that the extracellular inhibitors *SFRP1*, *SFRP4*, as well as the ligand *WNT5A* were significantly upregulated in OA cartilage ([**Table 3**](#table3-1947603511414178){ref-type="table"}). The intracellular target and effector genes *FOSL1* and *NFATC2* also displayed a significant upregulation in OA cartilage, whereas the receptor *FZD8* displayed a similar trend but not a significant upregulation (*P* = 0.052). On the other hand, no significant difference was detected with regard to the expression of the downstream target gene *PPARD* in OA and ND cartilage (*P* = 0.082) ([**Table 3**](#table3-1947603511414178){ref-type="table"}).

###### 

Quantitative PCR Analysis of WNT-Related Genes

           ND    95% CI   OA      95% CI   *P* Value
  -------- ----- -------- ------- -------- -----------
  SFRP4    1.0   0.87     33.64   16.98    0.004
  FOSL1    1.0   0.72     14.26   8.29     0.004
  WNT5A    1.0   0.37     10.66   5.55     0.004
  SFRP1    1.0   0.72     8.35    7.67     0.030
  NFATC2   1.0   0.32     7.90    2.54     0.004
  FZD8     1.0   0.74     2.76    0.83     0.052
  PPARD    1.0   0.36     0.58    0.13     0.082

Note: Quantitative real-time PCR verification of genes, which displayed the highest fold change (FC) in this extended microarray analysis. Error presenting the uncertainty with a 95% confidence interval (CI). Cartilage biopsies from 6 normal donors (NDs) and 5 osteoarthritis (OA) donors were studied; each sample was analyzed in duplicates.

Increased Protein Expression of AXIN2, DKK1, DKK3, and WNT5A in OA Cartilage {#section22-1947603511414178}
----------------------------------------------------------------------------

The spatial localization of AXIN2, DKK1, DKK3, and WNT5A was studied in OA and ND cartilage biopsies using immunohistochemistry in order to verify the microarray data. These markers were investigated due to their involvement in inhibiting the canonical WNT pathway (DKK1, DKK3, and AXIN2) as well as activating the Ca^2+^ pathway (WNT5A). Expression of AXIN2 and DKK1 in ND cartilage was localized to the uppermost cell layers, whereas their expression was extended to the cells located in the deeper layers in OA cartilage ([**Fig. 3A**](#fig3-1947603511414178){ref-type="fig"}-[**D**](#fig3-1947603511414178){ref-type="fig"}). Abundant expression of DKK3 and WNT5A was detected in OA cartilage, while a lower expression, somewhat more restricted to the superficial zone, was detected in ND cartilage ([**Fig. 3E**](#fig3-1947603511414178){ref-type="fig"}-[**H**](#fig3-1947603511414178){ref-type="fig"}).

![Verification of the microarray results using immunohistochemistry. Stainings with antibodies against AXIN2 (**A**, **B**), DKK1 (**C**, **D**), DKK3 (**E**, **F**), and WNT5A (**G**, **H**) in normal donor (ND) (**A**, **C**, **E**, **G**) and OA (**B**, **D**, **F**, **H**) cartilage. Nuclei were stained blue with 4',6-diamidino-2-phenylindol.](10.1177_1947603511414178-fig3){#fig3-1947603511414178}

WNT Signal Transduction Pathway Differentially Expressed in OA Cartilage {#section23-1947603511414178}
------------------------------------------------------------------------

The protein-protein interaction network analysis of genes, classified both as signal transducers and differentially expressed in OA cartilage (performed with raw data originated from the microarray analysis), revealed 7 hub genes associated with the WNT signaling pathway including the receptors *FZD1*, *FZD7*, *FZD8*, and *FZD10*; the extracellular inhibitors *SFRP1* and *SFRPP4*; and the ligand *WNT5A* ([**Fig. 4**](#fig4-1947603511414178){ref-type="fig"}). The presence of these hub genes demonstrates that the WNT signaling pathway is dysregulated in OA cartilage (for more general information, see [**Table 4**](#table4-1947603511414178){ref-type="table"}).

![Protein-protein interaction network of genes differentially regulated comparing OA and ND cartilage and classified as signal transducers, generated with the STRING search tool. Hub genes linked to WNT signaling, identified as genes with interaction with at least 5 other regulated genes, are marked in red. Other WNT-associated genes are marked by yellow boxes.](10.1177_1947603511414178-fig4){#fig4-1947603511414178}

###### 

Genes Revealed in the Protein-Protein Interaction Analysis

  Gene Name                                                                 Gene Symbol   Probe ID        Public ID   FC OA versus ND   *P* Value
  ------------------------------------------------------------------------- ------------- --------------- ----------- ----------------- -------------
  Interleukin 8                                                             IL8           211506_s\_at    AF043337    136.4             6.68882E-20
  Chemokine ligand 4                                                        CCL4          204103_at       NM_002984   29.1              1.38807E-17
  Adenylate cyclase 7                                                       ADCY7         203741_s\_at    NM_001114   28.6              1.09951E-16
  Fc fragment of IgE, high affinity I, receptor for γ polypeptide           FCER1G        1554899_s\_at   ---         20.4              5.63102E-12
  Insulin-like growth factor 1                                              IGF1          209541_at       AI972496    17.6              4.53068E-8
  Phosphodiesterase 4B, cAMP specific                                       PDE4B         203708_at       NM_002600   16.8              2.47481E-16
  Wingless-type MMTV integration site family, member 5                      WNT5A         205990_s\_at    NM_003392   16.0              6.92735E-15
  Secreted frizzled-related protein 4                                       SFRP4         204051_s\_at    AW089415    14.2              1.38979E-25
  Frizzled homolog 8                                                        FZD8          227405_s\_at    AW340311    13.4              8.92757E-26
  Insulin-like growth factor binding protein 4                              IGFBP4        201508_at       NM_001552   11.0              7.25381E-12
  Interleukin-1β                                                            IL1B          205067_at       NM_000576   10.4              4.28733E-16
  Guanylate cyclase 1, soluble, α 3                                         GUCY1A3       221942_s\_at    AI719730    9.6               1.45456E-12
  Chloride intracellular channel 3                                          CLIC3         219529_at       NM_004669   8.4               3.06828E-9
  Secreted frizzled-related protein 1                                       SFRP1         202037_s\_at    NM_003012   8.1               1.45767E-12
  Chemokine (C-X-C motif) ligand 1                                          CXCL1         204470_at       NM_001511   7.9               2.24479E-15
  ADP ribosylation factor--like 4A                                          ARL4A         205020_s\_at    NM_005738   7.3               3.32194E-9
  Neuropilin 1                                                              NRP1          210510_s\_at    AF145712    6.9               2.562E-14
  Frizzled homolog 10                                                       FZD10         219764_at       NM_007197   6.7               6.72813E-30
  Endothelial differentiation, sphingolipid G protein--coupled receptor 3   EDG3          228176_at       ---         6.4               1.98944E-10
  Fibroblast growth factor 1                                                FGF1          205117_at       X59065      6.3               6.13851E-12
  Vascular endothelial growth factor C                                      VEGFC         209946_at       U58111      5.8               1.9044E-15
  Insulin-like growth factor binding protein 5                              IGFBP5        211959_at       AW007532    5.5               4.0204E-28
  Interleukin-1 receptor--associated kinase 2                               IRAK2         231779_at       AI246590    5.5               5.16393E-10
  Guanine nucleotide binding protein γ 2                                    GNG2          224964_s\_at    AK026424    5.2               4.62131E-13
  Heparin-binding EGF-like growth factor                                    HBEGF         38037_at        M60278      4.9               9.22139E-11
  Guanine nucleotide binding protein γ 11                                   GNG11         204115_at       NM_004126   4.8               1.66689E-15
  EPH receptor A3                                                           EPHA3         206070_s\_at    AF213459    4.7               1.71399E-8
  Lymphocyte antigen 96                                                     LY96          206584_at       NM_015364   4.3               8.90125E-14
  Insulin-like growth factor binding protein 3                              IGFBP3        212143_s\_at    BF340228    4.2               5.24352E-10
  Frizzled homolog 7                                                        FZD7          203706_s\_at    NM_003507   4.0               3.13684E-24
  Guanylate cyclase 1, soluble, β 3                                         GUCY1B3       211555_s\_at    AF020340    3.9               8.58847E-8
  Deleted in liver cancer 1                                                 DLC1          210762_s\_at    AF026219    3.9               2.07307E-11
  Frizzled homolog 1                                                        FZD1          204452_s\_at    AF072872    3.8               3.07887E-13
  Toll-like receptor 4                                                      TLR4          221060_s\_at    NM_003266   3.7               1.04917E-8
  Cell division cycle 42                                                    CDC42         210232_at       M35543      3.7               1.28184E-13
  Casein kinase I ϵ                                                         CSNK1E        226858_at       ---         3.5               2.73695E-8
  T-cell lymphoma invasion and metastasis 1                                 TIAM1         213135_at       U90902      3.5               2.20078E-11
  Nuclear factor of κ light polypeptide gene enhancer in B-cells 1          NFκB1         209239_at       M55643      3.4               7.31975E-11
  EPH receptor A2                                                           EPHA2         203499_at       NM_004431   3.4               1.24766E-8
  Receptor-interacting serine-threonine kinase 2                            RIPK2         209545_s\_at    AF064824    3.4               6.04088E-12
  Rho GDP dissociation inhibitor β                                          ARHGDIB       1555812_a\_at   ---         3.1               1.29293E-12
  WNT inhibitory factor 1                                                   WIF1          204712_at       NM_007191   3.1               2.26111E-5
  ADP ribosylation factor 6                                                 ARF6          203312_x\_at    NM_001663   2.3               1.20473E-10
  Period homolog 1                                                          PER1          36829_at        AF022991    −2.6              4.15062E-16
  V-akt murine thymoma viral oncogene homolog 3                             AKT3          212607_at       N32526      −3.0              3.91207E-15
  Very low density lipoprotein receptor                                     VLDLR         209822_s\_at    L22431      −3.2              3.87155E-14
  CD79b molecule, immunoglobulin-associated β                               CD79B         205297_s\_at    NM_000626   −3.3              1.07823E-10
  Phosphoinositide 3-kinase, regulatory subunit 1                           PIK3R1        212249_at       AI934473    −4.2              9.10041E-13
  Tripartite motif containing 23                                            TRIM23        210994_x\_at    AF230398    −4.5              3.92373E-21
  Neuroepithelial cell transforming 1                                       NET1          201829_at       AW263232    −4.8              1.24765E-44
  FYVE, RhoGEF and PH domain containing 4                                   FGD4          230559_x\_at    AI277617    −6.7              4.07098E-11
  Interleukin 6 receptor                                                    IL6R          226333_at       ---         −6.8              1.22076E-29
  Family with sequence similarity 13, member A                              FAM13A1       202973_x\_at    ---         −7.0              1.13137E-17
  V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog             KIT           205051_s\_at    NM_000222   −7.5              4.08763E-9
  Ras homolog gene family, member B                                         RHOB          1553965_x\_at   ---         −8.4              7.02128E-17

Note: All genes, both WNT and non-WNT related, revealed in the protein-protein interaction analysis. Expression differences are given as fold change (FC). Genes with a positive FC are upregulated in osteoarthritic (OA) cartilage when compared with normal donor (ND) cartilage. Performed with raw data originated from the microarray analysis.

Increased Expression of DKK1, FOSL1, SFRP4, and WNT5A in Interleukin-1β--Stimulated Chondrocytes {#section24-1947603511414178}
------------------------------------------------------------------------------------------------

Chondrocytes from both OA and ND cartilage were stimulated with interleukin-1β in order to study if the increased production of this cytokine in OA could explain the increased expression of WNT-related genes. Real-time PCR demonstrated that interleukin-1β stimulation induced significantly increased expression of *FOSL1* and *WNT5A* in chondrocytes derived from both ND and OA cartilage. The same trend was observed in *SFRP4* expression (except for OAChon3) ([**Fig. 5A**](#fig5-1947603511414178){ref-type="fig"}-[**C**](#fig5-1947603511414178){ref-type="fig"}). No consistent upregulated expression of *DKK1* was detected after interleukin-1β stimulation, while a somewhat downregulated expression of *FZD1* was detected ([**Fig. 5D**](#fig5-1947603511414178){ref-type="fig"} and [**5E**](#fig5-1947603511414178){ref-type="fig"}). No significant differences in the expression of Wnt markers were detected between ND and OA chondrocytes cultured in monolayer (data not shown).

![Real-time PCR analysis after IL-1β stimulation. Gene expression analysis of *FOSL1*, *SFRP4*, *WNT5A*, *DKK1*, and *FZD1* after interleukin-1β stimulation of chondrocytes from normal cartilage (indicated as NDChon1-3 in the chart) and OA cartilage (indicated as OAChon4-6 in the chart). Error bars present the uncertainty with a 95% confidence interval. Cartilage biopsies from 3 normal donors (NDs) and 3 OA donors were studied; each sample was analyzed in duplicates.](10.1177_1947603511414178-fig5){#fig5-1947603511414178}

Discussion {#section25-1947603511414178}
==========

This study is the first that comprehensively analyzed the expression of WNT markers in human OA cartilage using genome-wide microarrays. We have earlier reported the results from a broad gene expression comparison of ND and OA cartilage and here focus on the expression of WNT markers.^[@bibr17-1947603511414178]^ One important issue in this type of study is the source of biological material. In this study, we chose to analyze cartilage obtained *post mortem* from donors having no history of OA as well as patients diagnosed with OA. One drawback with this approach is that there is a difference in age between the 2 groups of donors compared, and it is further possible that these 2 groups of donors have different levels of physical activity. Both these factors can, of course, affect the gene expression of the chondrocytes.^[@bibr23-1947603511414178],[@bibr24-1947603511414178]^ Another alternative approach is to use macroscopically healthy and diseased cartilage from the same OA patient. This setup overcomes the issues described above, but on the other hand, possible genetic differences will not be detected, and what macroscopically appears to be healthy cartilage might still differ from "true" healthy cartilage. OA is further more common on the medial part of the knee so taking OA and ND cartilage from the same joint will thus likely result in a comparison of cartilage from different parts of the knee, which also is known to affect gene expression.^[@bibr25-1947603511414178],[@bibr26-1947603511414178]^ We have characterized our biopsies both macroscopically, microscopically, as well as using whole-genome microarray analysis and demonstrated typical traits of ND and OA cartilage as seen in the literature^[@bibr17-1947603511414178],[@bibr27-1947603511414178]^ and therefore consider the differences detected in WNT signaling in our study highly likely to be due to OA.

The KEGG pathway analysis, demonstrating differently expressed WNT signaling in OA compared to ND cartilage, encouraged us to further investigate the WNT pathway. This approach resulted in the discovery of an array of WNT-related genes, not previously associated with OA, displaying significantly altered expression in OA compared to ND human articular cartilage. Besides the results from the pathway analysis, the main finding of this study is the discovery of a panel of inhibitors of the canonical and planar cell polarity pathways displaying significantly increased expression in OA cartilage. Moreover, the protein-protein interaction network analysis, demonstrating that several hub genes within the WNT signaling pathway were dysregulated in OA compared to ND cartilage, gave further indications of a different signaling profile in OA-affected cartilage. Our results further demonstrate that the expression of several of these genes significantly increased after cytokine treatment, which at least partly might explain their increased expression in OA cartilage. In fact, the expression of IL-β was significantly increased (10.4 FC) in OA compared to healthy cartilage ([**Table 4**](#table4-1947603511414178){ref-type="table"}). Moreover, previous studies have demonstrated upregulation of several WNT-related genes associated with IL-1β stimulation.^[@bibr13-1947603511414178],[@bibr28-1947603511414178],[@bibr29-1947603511414178]^

In this study, both *DKK1* and *DKK3* were found to be highly expressed in OA cartilage. DKK1 interacts with LRP5 and LRP6 and the transmembrane receptors KRM1 and KRM2 and prevents activation of the canonical WNT network.^[@bibr30-1947603511414178]^ In accordance with our results, increased serum levels of DKK1 have been detected in patients with OA,^[@bibr28-1947603511414178],[@bibr31-1947603511414178]^ and it is likely that DKK1 detected in serum originates from the OA-affected cartilage. However, the impact of this increased expression is still unknown, but it has been associated both with reduced risk for cartilage loss^[@bibr31-1947603511414178]^ and chondrocyte apoptosis.^[@bibr28-1947603511414178]^ Additionally, in line with our results, Meng *et al.* observed an upregulation of DKK3 in experimentally induced OA cartilage.^[@bibr32-1947603511414178]^

Our microarray data further demonstrated increased expression of other extracellular inhibitors of canonical WNT signaling, including *WIF1*, *SFRP1*, and *SFRP4* (results for *SFRP1* and *SFRP4* were also verified by real-time PCR). Verification by immunohistological stainings revealed expression of DKK1 and DKK3 in the entire sections of OA cartilage, but only in the surface zone in ND cartilage. This could be due to the phenotypic and metabolic changes that OA chondrocytes display among the zones in articular cartilage compared to ND chondrocytes. WIF1 and SFRP are antagonists to the WNT signaling network, resulting in an inhibition of both the canonical and planar cell polarity pathways.^[@bibr33-1947603511414178]^ Moreover, the protein interaction analysis conducted in this study revealed interactions between *FZD8*, *SFRP1*, and *SFRP4*, which give further support to the suggestion of inhibited WNT pathways. Our study is the first demonstrating WIF1 in OA cartilage, while both SFRP1 and SFRP4 have earlier been detected in OA synovium^[@bibr34-1947603511414178]^ but have not previously been associated with OA chondrocytes. SFRP1, SFRP3, and SFRP5 have recently been demonstrated to be expressed in proliferating chondrocytes and at the prehypertrophic stage during mouse limb formation.^[@bibr7-1947603511414178]^ The significantly increased expression of *SFRP1* and *SFRP4* detected in OA cartilage might thus result in increased proliferation and hypertrophy characteristic of OA cartilage. Our results further demonstrate that the increased expression of *DKK1*, *FOSL1*, *SFRP4*, and *WNT5A* in OA cartilage might partly be due to the increased release of cytokines characteristic of OA chondrocytes. In accordance with our data, Weng *et al*. have correlated both tumor necrosis factor-α and interleukin-1β production to DKK1 expression in OA cartilage.^[@bibr28-1947603511414178]^

Other signs of an inhibited canonical WNT signaling pathway in OA cartilage were suggested in this study by a high expression of several genes involved in β-catenin phosphorylation and its destruction, such as *AXIN2*, *SOX17*, and *TAX1BP3*. AXIN2 expression has been reported to increase in response to mechanical injury to human articular cartilage^[@bibr35-1947603511414178]^ and is known to assemble proteins involved in β-catenin phosphorylation and degradation. AXIN2 has further been suggested to participate in a negative feedback loop limiting the duration/intensity of a WNT-initiated signal.^[@bibr36-1947603511414178],[@bibr37-1947603511414178]^ Immunohistological staining performed in our study exhibited expression of AXIN2 in the uppermost layers of ND cartilage; meanwhile, OA cartilage displayed AXIN2 expression in the entire section, which could implicate that AXIN2 promotes restriction of WNT network signals in OA cartilage. SOX17 interacts directly with both β-catenin and TCF/LEF to trigger degradation of the β-catenin complex, thus inhibiting WNT signaling.^[@bibr38-1947603511414178]^ TAX1BP3, also referred to as TIP1, has been suggested to repress transcriptional activity of β-catenin, possibly by affecting the stability or subcellular localization of β-catenin.^[@bibr39-1947603511414178]^ Taken together, these findings could suggest that the activity/stability of β-catenin is affected in OA cartilage, thus potentially resulting in an inhibited canonical WNT signaling pathway. On the contrary, other studies have reported increased protein expression of β-catenin in human OA cartilage,^[@bibr15-1947603511414178]^ implicating an activated canonical WNT signaling. Additionally, the study also demonstrated significantly higher expression of the noncanonical ligand *WNT5A*, which is in line with our results (see below) and is further suggested by Zhu *et al.* as an upregulation of Ca^2+^/WNT signaling pathway via β-catenin. Although the expression of β-catenin is not ascertained within this study, and we cannot rule out the possibility that downstream signaling is affected by other compensation mechanisms than those revealed in this microarray analysis, this thus suggests that the canonical WNT signaling pathway is partly inhibited in OA cartilage.

Finally, our analysis further revealed an increased expression in OA cartilage of several intranuclear inhibitors of canonical WNT signaling, such as *TLE4*, but also decreased expression of the transcription factor *TCF7L2* (also referred to as *TCF4*). This might result in an inhibited transcription of downstream WNT-related genes. On the other hand, the microarray data demonstrated increased expression in OA cartilage of *FOSL1* and *PPARD.* However, verification of the microarray expression by PCR only revealed a significantly increased expression of *FOSL1* in OA cartilage. *FOSL1* is involved in WNT signaling pathway (according to the KEGG database) and is suggested as a β-catenin/WNT signaling target gene, transcribed when WNT signaling is activated,^[@bibr40-1947603511414178],[@bibr41-1947603511414178]^ thus implying increased canonical WNT signaling. This is not in accordance with our results obtained for upstream genes within the canonical WNT pathway, suggesting decreased signaling through this pathway, but could thus indicate a partly inhibited canonical WNT signaling pathway. However, this gene is also part of another WNT signaling cascade, the Ca^2+^/WNT signaling pathway,^[@bibr42-1947603511414178]^ which, suggested by our study, was activated in OA cartilage and thus might explain the increased expression of *FOSL1* (see discussion below). FOSL1, also referred to as FRA1, is further also part of the AP1 complex, which has been implicated in the regulation of matrix metalloproteinase 1 (MMP1) expression in OA cartilage.^[@bibr43-1947603511414178],[@bibr44-1947603511414178]^ Moreover, ectopic expression of FRA1 induces increased bone mass,^[@bibr45-1947603511414178]^ which is interesting because increased subchondral plate thickness is a characteristic of OA pathogenesis. However, because AP-1 genes have further been implicated in the pathogenesis of cancer in various tissues and are commonly activated in response to inflammatory stimuli,^[@bibr46-1947603511414178],[@bibr47-1947603511414178]^ the high expression in OA cartilage thus not unanimous demonstrates WNT activation.

With regard to markers of the planar cell polarity pathway, our study demonstrated that transcription of the gene encoding the transmembrane protein *VANGL1* was increased in OA cartilage. Furthermore, *DAAM2*, *PRICKLE2*, and *DVL2* encoding cytoplasmatic proteins, interacting with FZD and VANGL1, displayed decreased expression in OA cartilage. It has earlier been demonstrated that the proteins encoded by these genes interact with FZD and VANGL1, forming a multiprotein complex that transmit signaling to the nucleus. The decreased expression of these genes demonstrated in this study suggests not only the canonical WNT signaling pathway as partly inhibited in OA cartilage but also the planar cell polarity pathway.^[@bibr48-1947603511414178]^ However, our study further suggests that the Ca^2+^/WNT signaling pathway was activated in OA cartilage. This was demonstrated by increased expression of the *WNT5A* ligand in OA cartilage, causing intracellular calcium flux leading to activation of Ca^2+^-dependent effector molecules such as *CAMKII*, *NFAT5*, and *NFATC2*, which was also demonstrated to be upregulated in OA cartilage. Interestingly, CAMKII has been implicated as a key factor in impact-induced chondrocyte death and presumably acts downstream of an increased concentration of cytoplasmic calcium.^[@bibr49-1947603511414178]^ Moreover, our study demonstrated that real-time PCR verification of the expression of *NFATC2* and *WNT5A* was in accordance with the results obtained from the microarray analysis. *NFATC2* is known to regulate chondrogenesis in adult mice, whereas an overexpression represses the mature phenotype and extinguishes the cartilage phenotype.^[@bibr50-1947603511414178]^ Extracellular matrix--degrading proteases have been suggested as downstream targets of *NFATC2* activation.^[@bibr51-1947603511414178]^ This further demonstrates the impact that WNT-related genes exert on the pathogenesis of OA and implicates *NFATC2* in the involvement of the OA chondrocyte phenotypic change and articular cartilage destruction process.

WNT5A microarray expression was further verified by immunohistological staining, demonstrating WNT5A expression in both the superficial zone and the deeper layers of OA cartilage. ND cartilage, on the other hand, displayed a somewhat more restricted WNT5A expression, located in the superficial zone. WNT5A has earlier been shown to exert an inhibitory effect on type II collagen expression in chondrocytes and is indicated to increase in gene expression related to IL-1β stimulation.^[@bibr13-1947603511414178],[@bibr29-1947603511414178]^ This is in accordance with our result that demonstrated a significantly higher *WNT5A* expression after cytokine stimulation. Increased *WNT5A* expression associated with IL-1β stimulation is further implicated in the regulation of MMPs responsible for promoting cartilage destruction.^[@bibr29-1947603511414178]^ This is interesting to note because we have earlier discussed (see above) the involvement of the *FOSL1*, a suggested downstream target gene of Ca^2+^/WNT signaling pathway, in the regulation of MMP1.

This and the suggested activation of the Ca^2+^/WNT signaling pathway and its effector molecules in OA cartilage could thus, to some extent, explain the increased apoptosis detected in OA chondrocytes as well as the altered matrix composition seen in OA cartilage. Our data, which is an extension of a previously published article,^[@bibr17-1947603511414178]^ provide a basis for future studies on the function of numerous newly identified genes in OA pathogenesis and on their suitability as drug targets in OA.

Conclusion {#section26-1947603511414178}
==========

Our results demonstrate that WNT signaling is significantly altered in OA cartilage. The result suggests that the canonical and planar cell polarity pathways are partly inhibited while the Ca^2+^/WNT signaling pathway is activated.
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